What are Pfizer's total assets?

Pfizer (PFE) holds $207.62B in total assets, down 0.2% year over year.

How much debt does Pfizer have?

Pfizer carries $64.4B in total debt against $90.1B of shareholders' equity, a debt-to-equity ratio of 0.71.

How much cash does Pfizer have?

Pfizer holds $1.8B in cash and equivalents.

Can Pfizer cover its short-term obligations?

Its current ratio is 1.25 — current assets exceed current liabilities.

Where does Pfizer's balance sheet data come from?

Every line is extracted from Pfizer's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Pfizer PFE Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$1.2B+8.1%	$1.11B-62.1%	$2.92B+523%	$468M-76.4%
Short-term investments	$12.45B-35.9%	$19.43B+97.6%	$9.84B-55.9%	$22.32B-23.4%
Accounts receivable, net	$11.87B+3.6%	$11.46B-0.9%	$11.57B+5.6%	$10.95B-4.6%
Inventories	$2.37B-11.0%	$2.66B-41.7%	$4.57B-21.6%	$5.83B+521%
Work in process	$5.63B-7.7%	$6.1B+7.3%	$5.69B+3.1%	$5.52B+24.8%
Derivative assets	$532M-64.9%	$1.52B+117%	$700M-35.1%	$1.08B+11.4%
Total current assets	$42.9B-14.8%	$50.36B+16.2%	$43.33B-15.5%	$51.26B-14.1%
Property and equipment, net	$19.32B+5.0%	$18.39B-2.9%	$18.94B+16.4%	$16.27B+9.4%
Accumulated depreciation	$17.39B+5.5%	$16.48B+2.7%	$16.05B+5.7%	$15.17B+0.7%
Goodwill	$71.26B+4.0%	$68.53B+1.1%	$67.78B+31.9%	$51.38B+4.4%
Deferred tax assets	$2.4B+13.1%	$2.12B+232%	$640M-37.4%	$1.02B+193%
Equity securities	$2.6B-66.9%	$7.85B+53.2%	$5.12B+223%	$1.59B-70.4%
Total assets	$208.16B-2.5%	$213.4B-5.8%	$226.5B+14.9%	$197.21B+8.7%
Accounts payable	$5.24B-7.0%	$5.63B-16.1%	$6.71B-1.5%	$6.81B+22.1%
Current portion of long-term debt	$3B-20.0%	$3.75B+66.2%	$2.25B-12.0%	$2.56B+56.5%
Income taxes payable	$3.1B+6.6%	$2.91B+23.9%	$2.35B+48.0%	$1.59B+25.4%
Dividends payable	$2.45B+0.3%	$2.44B+2.7%	$2.37B+3.0%	$2.3B+2.4%
Total current liabilities	$36.98B-14.0%	$43B-10.0%	$47.79B+13.4%	$42.14B-1.2%
Long-term debt	$61.64B+7.4%	$57.41B-6.7%	$61.54B+87.1%	$32.88B-9.1%
Other non-current liabilities	$14.73B+4.1%	$14.15B-14.4%	$16.54B+25.5%	$13.18B+35.3%
Total liabilities	$3.25B-97.4%	$124.9B-9.0%	$137.21B+35.5%	$101.29B-2.6%
Additional paid-in capital	$94.47B+0.9%	$93.6B+1.0%	$92.63B+0.9%	$91.8B+1.3%
Retained earnings	$114.61B-1.8%	$116.73B-1.4%	$118.35B-5.8%	$125.66B+21.5%
Accumulated other comprehensive income (loss)	-$8.07B-2.9%	-$7.84B+1.5%	-$7.96B+4.1%	-$8.3B-40.8%
Treasury stock	$115.02B+0.2%	$114.76B+0.2%	$114.49B+0.5%	$113.97B+2.3%
Total stockholders' equity	$86.48B-2.0%	$88.2B-0.9%	$89.01B-6.9%	$95.66B+23.9%
Total liabilities and stockholders' equity	$208.16B-2.5%	$213.4B-5.8%	$226.5B+14.9%	$197.21B+8.7%
Allowance for Doubtful Accounts	$427M-2.5%	$438M-6.8%	$470M+4.7%	$449M-8.7%
Available For Sale Securities Debt Securities Current	$9.18B-15.6%	$10.88B+147%	$4.4B-76.5%	$18.74B-14.9%
Derivatives	$416M—	——	——	——
Finished goods	$4.11B+9.0%	$3.78B+8.0%	$3.5B+34.3%	$2.6B-28.5%
Materials and supplies	$907M-7.1%	$976M-3.1%	$1.01B+17.2%	$859M-13.6%
Other current assets	$2.81B-34.0%	$4.25B-13.4%	$4.91B-2.1%	$5.02B+31.3%
Securities Received As Collateral	——	——	——	——
Total Debt Securities (Trading and AFS)	$9.91B—	——	——	——
Derivative Assets, Current	$416M—	——	——	——
Derivative Assets - Fair Value	$116M—	——	——	——
Available-for-Sale and Held-to-Maturity Debt Securities	$9.91B-16.2%	$11.81B+131%	$5.12B-76.5%	$21.81B-11.3%
Deferred Tax Assets and Other Non-Current Assets	$9.63B-1.9%	$9.82B-21.3%	$12.47B-5.3%	$13.16B+71.4%
Derivative Assets, Non-Current	$116M—	——	——	——
Equity Securities Without Readily Determinable Fair Value - Cumulative Impairment Loss	——	——	——	——
Equity Securities Without Readily Determinable Fair Value - Cumulative Upward Adjustments	——	——	——	——
Equity Securities (Non-Current)	$642M-48.5%	$1.25B-55.2%	$2.78B-2.0%	$2.84B-26.8%
Indefinite-Lived Intangible Assets	$22.22B+13.6%	$19.56B-21.1%	$24.78B+88.4%	$13.16B+197%
Indefinite-Lived Intangible Assets, Gross	$22.22B+13.6%	$19.56B-21.1%	$24.78B+88.4%	$13.16B+197%
Indefinite-Lived Research and Development Assets	$22.22B+13.6%	$19.56B-21.1%	$24.78B+88.4%	$13.16B+197%
Indefinite-Lived Trademarks	$22.22B+13.6%	$19.56B-21.1%	$24.78B+88.4%	$13.16B+197%
Long-term marketable securities	$1M—	$0-100%	$150M-57.4%	$352M-32.4%
Noncurrent deferred tax assets and other noncurrent tax assets	$9.7B+12.0%	$8.66B+134%	$3.71B-44.6%	$6.69B+100%
Intangible assets — net	$31.51B-12.1%	$35.85B-10.6%	$40.12B+32.8%	$30.22B+45.9%
Held To Maturity Securities Noncurrent	$48M+6.7%	$45M-4.3%	$47M-2.1%	$48M+41.2%
Other intangible assets—net	$53.73B-3.0%	$55.41B-14.6%	$64.9B+49.6%	$43.37B+72.5%
Other non-current assets	$9.63B-1.9%	$9.82B-21.3%	$12.47B-5.3%	$13.16B+71.4%
Strategic investments	$1.62B-27.2%	$2.23B-40.3%	$3.73B-7.6%	$4.04B-20.1%
Current tax assets	$3.97B+19.7%	$3.31B-16.7%	$3.98B+11.2%	$3.58B-16.2%
Other Investments	$1.62B-27.2%	$2.23B-40.3%	$3.73B-7.6%	$4.04B-20.1%
Software and Technology Licenses, Net	$9.63B-1.9%	$9.82B-21.3%	$12.47B-5.3%	$13.16B+71.4%
Accrued Manufacturing Costs	$3.61B-5.9%	$3.84B+38.3%	$2.78B-18.5%	$3.41B+2.3%
Compensation and benefits	$3.61B-5.9%	$3.84B+38.3%	$2.78B-18.5%	$3.41B+2.3%
Other accrued liabilities	$19.43B-1.5%	$19.72B-4.0%	$20.54B-9.0%	$22.57B-9.5%
Other short-term debt	$157M-79.2%	$755M+200%	$252M-34.5%	$385M-36.4%
Derivative Liabilities - Fair Value	$1.46B+6.7%	$1.37B-3.8%	$1.42B-24.8%	$1.89B+114%
Supplier Finance Program Obligations	$574M-16.6%	$688M-13.0%	$791M-6.8%	$849M—
Total Debt, Gross	$3.16B-54.6%	$6.96B-33.5%	$10.47B+257%	$2.94B+31.0%
Liability For Uncertain Tax Positions Noncurrent	$3.59B-41.2%	$6.11B-28.4%	$8.53B-13.0%	$9.81B-13.4%
Retirement and nonpension postretirement benefit obligations	$2.04B-3.5%	$2.12B-2.4%	$2.17B-3.7%	$2.25B-39.6%
Debt Securities (Trading and AFS) - Accumulated Gross Unrealized Gain	$3M-62.5%	$8M+33.3%	$6M-98.0%	$304M+2,071%
Debt Securities (Trading and AFS) - Accumulated Gross Unrealized Loss	$35M-72.9%	$129M+706%	$16M-69.8%	$53M-80.0%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$481M+0.2%	$480M+0.4%	$478M+0.4%	$476M+0.6%
Gross Assets/Liabilities	$1.46B+6.7%	$1.37B-3.8%	$1.42B-24.8%	$1.89B+114%
Allowance for doubtful accounts	$427M-2.5%	$438M-6.8%	$470M+4.7%	$449M-8.7%
Business Combination, Contingent Consideration, Liability, Noncurrent	$1.7B—	——	——	——
Business Combination, Contingent Consideration, Liability, Current	$95M—	——	——	——
Collateral already posted, aggregate fair value	——	——	——	——
Short-term debt and current portion of long-term debt	$3.15B-54.6%	$6.95B-32.9%	$10.35B+251%	$2.95B+31.4%
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$3M-75.0%	$12M-90.1%	$121M—	——
Debt Securities, Amortized Cost Basis	$9.94B-16.7%	$11.94B+133%	$5.13B-76.2%	$21.56B-13.2%
Debt Securities Maturities, After Year Five, Fair Value	——	——	——	——
Debt Securities Maturities, Next Twelve Months, Fair Value	——	——	——	——
Debt Securities Maturities, Year Two Through Five, Fair Value	——	——	——	——
Deferred income taxes	$2.4B+13.1%	$2.12B+232%	$640M-37.4%	$1.02B+193%
Derivatives	$116M—	——	——	——
Derivative Liability	$1.46B+6.7%	$1.37B-3.8%	$1.42B-24.8%	$1.89B+114%
Derivative, Net Liability Position, Aggregate Fair Value	——	——	——	——
Equity method investments (Note 11)	$235M+8.3%	$217M-98.1%	$11.64B+5.5%	$11.03B-33.0%
Long-term equity securities held in trust	$146M—	——	——	——
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$1.79B+246%	$517M—	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	$72.5B+7.3%	$67.55B+7.5%	$62.83B+7.3%	$58.55B+4.9%
Gross Carrying Amount	$104.01B+0.6%	$103.4B+0.4%	$102.94B+16.0%	$88.76B+16.0%
Fair value hedge adjustments on discontinued hedges	$821M—	——	——	——
Carrying values of hedged liabilities	$7.11B—	——	——	——
Cumulative amount of fair value hedging adjustment	-$163M—	——	——	——
Trademarks	$22.22B+13.6%	$19.56B-21.1%	$24.78B+88.4%	$13.16B+197%
Indefinite- lived intangible impairment	$126.23B+2.7%	$122.96B-3.7%	$127.73B+25.3%	$101.92B+25.9%
Liabilities, Current, Fair Value Disclosure	$523M—	——	——	——
Liabilities, Noncurrent, Fair Value Disclosure	$2.73B—	——	——	——
Insurance contracts	$999M—	——	——	——
Current portion of long-term debt, principal amount	$3B-20.0%	$3.75B+66.7%	$2.25B-11.8%	$2.55B+55.9%
Noncontrolling interests in subsidiaries	$299M+1.7%	$294M+7.3%	$274M+7.0%	$256M-2.3%
Other Assets, Noncurrent, Fair Value Disclosure	$1.12B—	——	——	——
Private equity securities at cost	$696M-3.2%	$719M-4.8%	$755M-5.6%	$800M+28.4%
Total accrued rebates and other sales-related accruals	$11.67B+7.8%	$10.82B+20.1%	$9.01B+34.1%	$6.72B—
Restructuring Reserve	$1.91B-9.9%	$2.12B+6.6%	$1.99B+65.1%	$1.2B+12.4%
Threshold for disclosure of proceedings under environmental laws	——	——	——	——
Long-term income taxes	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Pfizer.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Pfizer's total assets?: Pfizer (PFE) holds $207.62B in total assets, down 0.2% year over year.
How much debt does Pfizer have?: Pfizer carries $64.4B in total debt against $90.1B of shareholders' equity, a debt-to-equity ratio of 0.71.
How much cash does Pfizer have?: Pfizer holds $1.8B in cash and equivalents.
Can Pfizer cover its short-term obligations?: Its current ratio is 1.25 — current assets exceed current liabilities.
Where does Pfizer's balance sheet data come from?: Every line is extracted from Pfizer's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.